Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib
ABSTRACT Introduction Ruxolitinib was the first JAK2 inhibitor approved for the treatment of primary and secondary myelofibrosis. It is currently used worldwide as first‐line therapy for advanced disease (intermediate‐2 and high‐risk) and is effective in polycythaemia vera (PV) and essential thrombo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | eJHaem |
| Online Access: | https://doi.org/10.1002/jha2.70007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|